Haematologica (Aug 2016)
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis
- Koji Sasaki,
- Hagop Kantarjian,
- Elias Jabbour,
- Farhad Ravandi,
- Koichi Takahashi,
- Marina Konopleva,
- Gautam Borthakur,
- Guillermo Garcia-Manero,
- William Wierda,
- Naval Daver,
- Preetesh Jain,
- Toshihisa Satta,
- Sherry Pierce,
- May Beth Rios,
- Jorge E. Cortes
Affiliations
- Koji Sasaki
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan
- Hagop Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Elias Jabbour
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Farhad Ravandi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Koichi Takahashi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Marina Konopleva
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Gautam Borthakur
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Guillermo Garcia-Manero
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- William Wierda
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Naval Daver
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Preetesh Jain
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Toshihisa Satta
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Sherry Pierce
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- May Beth Rios
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Jorge E. Cortes
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- DOI
- https://doi.org/10.3324/haematol.2015.139089
- Journal volume & issue
-
Vol. 101,
no. 8
Abstract
No abstracts available.
